Quantum Biopharma Ltd. Files September 2025 6-K Report
Ticker: QNTM · Form: 6-K · Filed: Sep 24, 2025 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Sep 24, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-private-issuer, reporting-compliance
TL;DR
Quantum Biopharma (formerly FSD Pharma) filed its monthly 6-K report on Sept 24, 2025, confirming its status as a foreign private issuer.
AI Summary
Quantum Biopharma Ltd. filed a Form 6-K on September 24, 2025, reporting for the month of September 2025. The company, formerly known as FSD Pharma Inc. until March 27, 2019, is based in Toronto, Ontario, Canada. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Quantum Biopharma's status as a foreign private issuer. It confirms ongoing reporting compliance.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information that would typically indicate increased risk.
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Filer of the report
- FSD Pharma Inc. (company) — Former name of Quantum Biopharma Ltd.
- September 24, 2025 (date) — Filing date
- Toronto, Ontario (location) — Company's principal executive office location
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
When was Quantum Biopharma Ltd. formerly known as FSD Pharma Inc.?
Quantum Biopharma Ltd. was formerly known as FSD Pharma Inc. until March 27, 2019.
Where is Quantum Biopharma Ltd.'s principal executive office located?
Quantum Biopharma Ltd.'s principal executive office is located at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9.
Does Quantum Biopharma Ltd. file annual reports under Form 20-F or Form 40-F?
Quantum Biopharma Ltd. indicates it files annual reports under cover of Form 20-F.
What period does this Form 6-K report cover?
This Form 6-K reports for the month of September 2025.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2025-09-24 08:30:05
Filing Documents
- f6k_092425.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-25-006049.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: September 24, 2025 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated September 24, 2025